This guidance requires that clinicians undertaking the procedure in patients with low-grade dysplasia (LGD) or no dysphagia to make special arrangements for audit. NICE has identified relevant audit criteria and developed an audit tool (which is for use at local discretion).
This guidance should be read in conjunction with NICE's guideline on Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management.
The evidence considered by the Interventional Procedures Advisory Committee is described in the overview.
NICE has produced information for the public on this procedure. It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.